Biologic Therapies: Can They Help Kids with Inflammatory Diseases Grow Taller?
"A new study explores how biologic drugs can combat growth stunting in children with chronic inflammatory conditions, offering hope for improved height and overall well-being."
Chronic inflammatory connective tissue diseases (CTDs) can throw a wrench into a child's development, and one of the most concerning complications is stunted growth. These diseases, which include juvenile idiopathic arthritis (JIA), directly inflame the musculoskeletal system and often require treatment with glucocorticoids, both of which can significantly hinder a child's growth velocity.
For parents, watching their child struggle with a CTD is heartbreaking, and the added worry of growth impairment can feel overwhelming. Traditional treatments often come with a difficult choice: manage the inflammation but risk suppressing growth, or try to mitigate side effects and potentially allow the disease to progress. It's a tough balance, and finding the right path can be a maze of uncertainty.
But there's good news on the horizon! A recent study investigated the impact of biologic therapies on growth in children with CTDs, offering a beacon of hope for families seeking better outcomes. Biologic agents, designed to target specific components of the immune system, have shown promise in not only controlling inflammation but also in restoring normal growth patterns. Let's dive into the details of this research and explore how these innovative treatments could help children with CTDs reach their full potential.
Biologics and Growth in JIA
Children with juvenile idiopathic arthritis (JIA) often experience growth retardation, and a 2025 systematic review examined how biologic treatments affect growth in pediatric patients. The review reports that starting biologic therapy early may benefit children with growth delays or high disease activity because controlling systemic inflammation can reduce its negative effects on growth velocity and development. In a cohort of 100 prepubertal or early pubertal children with JIA treated with biologics but not growth hormone, mean growth velocity was low when biologic therapy began and improved during treatment. Tumor necrosis factor-alpha inhibitors accounted for 75.8% of biologic use in one source, with a mean follow-up of 2 years.
How Do Biologic Therapies Work to Promote Growth?
Biologic therapies are a game-changer in the treatment of CTDs because they address the root cause of growth impairment. Unlike traditional treatments that broadly suppress the immune system, biologics target specific molecules, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which drive inflammation. By precisely blocking these inflammatory signals, biologics can:
- Reduce Inflammation: By targeting specific inflammatory molecules, biologics dampen the inflammatory response within the musculoskeletal system, allowing for healthier bone and cartilage development.
- Restore Hormone Balance: Chronic inflammation can disrupt the delicate balance of hormones crucial for growth, such as growth hormone and insulin-like growth factor. Biologics help restore this balance, creating a more favorable environment for growth.
- Minimize Glucocorticoid Use: By effectively controlling inflammation, biologics often allow doctors to reduce the dosage of glucocorticoids, minimizing their growth-suppressing effects.
What the 2025 Review Found
A 2025 systematic review analyzed 12 selected studies of biologic therapy and growth in children with JIA. It found an overall significant improvement in growth parameters after therapies such as Etanercept and Tocilizumab. The review particularly reported increased growth velocity and improved height standard-deviation scores among children who had delayed growth at baseline.
Why Results Need Caution
Evidence of improved growth does not establish that every child will regain expected height, because growth outcomes may be influenced by disease severity, corticosteroid exposure, and other factors. The CHERISH tocilizumab trial excluded children receiving high doses of glucocorticoids, which may have raised the study population's baseline height standard-deviation scores because higher steroid exposure can be associated with more severe growth impairment. A 2014 study described biologics as potentially improving growth velocity by controlling systemic inflammation and reducing corticosteroids, while newer reviews still describe growth retardation in JIA as arising from multiple factors. Long-term growth-hormone treatment also remains subject to questions about safety, long-term effects, and how treatment should be individualized.
Biologics and Growth Hormone Are Different Comparisons
The listed growth-hormone research compares once-weekly pegylated recombinant human growth hormone with daily growth hormone in children, rather than directly comparing growth hormone with biologic therapy for inflammatory disease. One 2026 review examines long-acting versus daily growth hormone across 16 randomized controlled trials involving 2,435 pediatric patients with isolated growth hormone deficiency. Separately, a review of biologics for childhood asthma notes that pediatric evidence has lagged behind adult and adolescent research, although more recent studies have expanded the evidence base. These sources therefore support comparison of treatment schedules and evidence maturity, not a conclusion that one treatment is superior for inflammation-related growth impairment.
The Takeaway: A Brighter Future for Kids with CTDs
The findings of this study offer a reassuring message to families dealing with the challenges of CTDs: biologic therapies hold significant promise for restoring normal growth in children. By targeting the root causes of inflammation and reducing the need for harmful steroids, these innovative treatments can help children with CTDs reach their full growth potential and enjoy a better quality of life. If you're concerned about your child's growth while managing a CTD, talk to your doctor about whether biologic therapy might be a suitable option.
Growth May Follow Disease Control
A report on children with chronic inflammatory connective-tissue diseases states that effective biologic therapy can improve clinical condition while reducing disease activity and daily glucocorticosteroid doses. According to that report, growth rate may gradually accelerate and normalize as inflammation is controlled and steroid exposure decreases. The 2025 systematic review likewise focuses on growth retardation in children with JIA and describes biologic therapy as an important development in managing aggressive disease. These findings support viewing improved growth as a possible consequence of better disease control, rather than as a guaranteed direct height-building effect.
Inflammation, Steroids, and Development
Reports on children with chronic inflammatory connective-tissue diseases describe persistent disease activity and glucocorticosteroid exposure as factors relevant to impaired growth. Effective biologic therapy may help by reducing disease activity and lowering daily glucocorticosteroid doses, which can allow growth to accelerate and normalize gradually. Broader commentary on chronic inflammatory and autoimmune conditions states that ongoing systemic inflammation can disrupt normal growth patterns and may contribute to long-term height deficits and psychosocial effects. These potential benefits do not remove the need to account for the underlying disease and the individual child's treatment circumstances.